Filtros de búsqueda

Lista de obras de Alex J. Eustace

2D-DIGE analysis of phospho-enriched fractions from dasatinib-treated melanoma cell lines

artículo científico publicado en 2011

A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib

artículo científico publicado en 2017

A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.

artículo científico publicado en 2014

Artificial Neural Networks for Classification in Metabolomic Studies of Whole Cells Using 1H Nuclear Magnetic Resonance ⬇️

artículo científico publicado el 15 de septiembre de 2010

Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer

scientific article published on 28 January 2020

Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells

artículo científico publicado en 2019

Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers.

artículo científico publicado en 2018

Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL

scientific article published on 11 October 2018

Effects of HER family-targeting tyrosine kinase inhibitors on antibody-dependent cell-mediated cytotoxicity in HER2-expressing breast cancer

artículo científico publicado en 2020

Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours

artículo científico publicado en 2012

Frequency, impact and a preclinical study of novel gene family mutations in HER2-positive breast cancer

article

Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH)

artículo científico publicado en 2018

Growth factor receptor/steroid receptor cross talk in trastuzumab-treated breast cancer

artículo científico publicado en 2014

HER2-family signalling mechanisms, clinical implications and targeting in breast cancer

artículo científico publicado en 2014

Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.

artículo científico publicado en 2017

In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies.

artículo científico publicado en 2014

Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma

artículo científico publicado en 2015

Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasis.

artículo científico publicado en 2010

Metabolomic studies of human lung carcinoma cell lines using in vitro (1)H NMR of whole cells and cellular extracts.

artículo científico publicado en 2008

Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08-10 tria

scientific article published on 24 July 2019

Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines

artículo científico publicado en 2008

Predictive biomarkers for dasatinib treatment in melanoma

artículo científico publicado en 2014

Prospects for non-immunological molecular therapeutics in melanoma.

artículo científico publicado en 2010

RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

artículo científico publicado en 2016

The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells

artículo científico publicado en 2008

The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells.

artículo científico publicado en 2018

The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer

artículo científico publicado en 2016

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda